REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31

REGENERON PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$782.04−8.70 (-1.10%)

Close on Oct 19, 2026

Community

Notes and questions about Regeneron Pharmaceuticals from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Regeneron Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is REGN.

Revenue growth9.3% · median 10.3%

Operating margin24.7% · median 22.8%

Net margin27.9% · median 15.1%

Advertisement
300 × 250